EnglishEN
Zum Hauptinhalt springen

Chefarzt

Prof. Dr. med.
Aristoteles Giagounidis

Chefarzt

E-Mail schreiben

Name

Giagounidis

First Name

Aristoteles

Titel

Prof. Dr. med.

Date of birth

26.11.1966

Place of birth

St. Ingbert, Germany

Nationality

German

Medical director at

Klinik für Onkologie, Hämatologie und Palliativmedizin, Marien Hospital Düsseldorf GmbH, Rochusstr. 2, 40479 Düsseldorf, Germany
phone: +49(0)211 4400-2079 / fax: +49(0)211 4400-2089

University Education

and Professional Curriculum:

1986 to1992 

Medicine at Eberhard-Karls-Universität Tübingen, Germany

1992  

Doctorate thesis: A new fruktosamine test, Universität Tübingen, Germany

08/1992-02/1993

House Officer at Withybush General Hospital,
Haverfordwest, Wales, UK

02/1993 - 08/1993

House Officer at William Harvey Hospital in Ashford, Kent, UK

1992

licence to practice medicine, Regierungspräsidium Stuttgart, Germany

10/1993-10/1999

Senior House Officer at Heinrich-Heine-Universität Düsseldorf, Germany, Klinik für Hämatologie, Onkologie und klinische Immunologie, Direktor: Prof. Dr. W. Schneider

10/1999

Board certificate in Internal Medicine („Arzt für Innere Medizin“) at Ärztekammer Nordrhein, Düsseldorf, Germany

04/2008 

Board certificate in Hematology/Oncology (Schwerpunkt Hämatologie und Onkologie) Ärztekammer Nordrhein, Düsseldorf, Germany

10/1999-08/2012

Attending at Medizinische Klinik 2, St. Johannes Hospital, Duisburg, Germany

08/2008

Habilitation at Technische Universität Dresden, Germany

since 8/2008

lecturer at the University of Dresden, Germany

since 08/2008

member of the scientific advisory board of the Aplastic Anaemia & Myelodysplastic Syndromes Foundation, Rockville/MD, USA

6/2009 -09/2012

Head of Clinical Research Department at Medizinische Klinik 2, St. Johannes Hospital, Duisburg, Germany

since 09/2012

Head of Department of Oncology, Hematology and palliative Care, Marien Hospital Düsseldorf GmbH, Düsseldorf, Germany

Research

Myelodysplastic syndromes, especially 5q-syndrome, Immune thrombocytopenia

latest GCP update

29.08.2019 / Düsseldorf

Inspections

FDA (30.11-04.11.2005)
EMEA (30.05.-02.06.2006)
Zentrales Inspektorat für Klinische Prüfungen in NRW (13.01.2010)

Study experience (example)

Indikation

EudraCT No.

Phase

Role in study

Study period

MDS

UNK

II

PI

2003-2008

MDS

UNK

III

Investigator

2000-2008

MDS

UNK

III

PI

2004 – 07/2009

MDS

UNK

III

Investigator

2003 – 2008

AML

2005-005966-35

II

PI

2006 -

MDS

2005-000454-73

III

PI

2007 -2010

Hodgkin Lymphoma

2005-005144-62

III

PI

2005-

ITP

2006-003700-18

III

PI

2007-2010

NHL

2006-001641-33

II / III

PI

2008-

MDS

2007-002532-28

II

PI

2008 – 2009

ITP

2007-006081-15

 

PI

2008-2011

MDS

2007-007258-75

 

PI

2009-2011

AML

2008-004968-40

II

PI

2009-

Multiple Myeloma

2007-003945-33

 

PI

2009-

AML

2009-010114-30

II

PI

2010-2011

MDS

2009-011513-24

III

PI

2010-

ITP

2009-010421-39

 

PI

2010-2014

sAML / MDS

2009-015512-17

I / II

PI

2010-2012

CML

2009-017775-19

III

PI

2010-2014

ITP

2010-019987-35

II

PI

2010-2013

CML

2010-024262-22

III

PI

2012-

AML

2009-009916-33

II

PI

2012-

MDS

2010-022884-36

III

PI

2011-

MDS

2012-002523-14

II

PI

2013-

CML

2012-004092-40

II

PI

2013-

AML

2013-003191-12

III

PI

2015-

CMML

2014-000200-10

III

PI

2015-

AML

2014-001233-89

III

PI

2015-

Mamma-Ca.

2014-001502-18

III

PI

2015-

MDS / AML

2015-003596-30

II

PI

2016-

CML

2014-005531-13

II

PI

2016